2nd Quarter - Report

BIOMET, INC. for BIOMET, INC.

Period 2nd Quarter 2012 Filed Jul 20, 2012 Signed by Millard P. Plumlee, Associate General Counsel, Biomet, Inc.

Official filing
Firm
BIOMET, INC.
Client
BIOMET, INC.
Income
—
Expenses
$200,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 436 - Protect Medical Innovation Act of 2012; S.17-Medical Device Access & Innovation Act; S. 727, S.3187-Food & Drug Administration Safety & Innovation Act; physician-owned companies; Medicare payment policy; medical device excise tax (ACA)

LobbyistCovered position, as disclosed
WILLIAM C KOLTER —

Contacted: SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: S. 3187 (112th), S. 17 (112th), H.R. 436 (112th), S. 727 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.